Glucagon · source year
4 selected, source-linked Glucagon records carrying a 2022 source date. This is a navigational view of PeptideScanner’s selected coverage—not a complete research timeline or a statement about safety or effectiveness.
4 selected records.
1 represented type.
4 distinct public records.
Cited chronology
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT04042142 at 2026-07-30T19:32:59.855Z. Its registry update date was 2022-11-04, and PeptideScanner's reviewed identity mapping was glucagon.
Source: ClinicalTrials.gov ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT03255629 at 2026-07-30T19:35:26.311Z. Its registry update date was 2022-09-06, and PeptideScanner's reviewed identity mapping was glucagon.
Source: ClinicalTrials.gov ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT02748369 at 2026-07-30T19:36:31.410Z. Its registry update date was 2022-08-03, and PeptideScanner's reviewed identity mapping was glucagon.
Source: ClinicalTrials.gov ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT04007809 at 2026-07-30T19:38:43.098Z. Its registry update date was 2022-06-28, and PeptideScanner's reviewed identity mapping was glucagon.
Source: ClinicalTrials.gov ↗